title: Immunotherapy for cancer in the central nervous system: Current and future directions.
abstract: Glioblastoma multiforme (GBM) is the most common primary brain tumor in adults and still remains incurable. Although immunotherapeutic vaccination against GBM has demonstrated immune-stimulating activity with some promising survival benefits, tumor relapse is common, highlighting the need for additional and/or combinatorial approaches. Recently, antibodies targeting immune checkpoints were demonstrated to generate impressive clinical responses against advanced melanoma and other malignancies, in addition to showing potential for enhancing vaccination and radiotherapy (RT). Here, we summarize the current knowledge of central nervous system (CNS) immunosuppression, evaluate past and current immunotherapeutic trials and discuss promising future immunotherapeutic directions to treat CNS-localized malignancies.
authors.affiliation: Commitee on Cancer Biology; Department of Pathology, The University of Chicago, Chicago, IL, USA.
authors.forename: David C
authors.initials: DC
authors.lastname: Binder
authors.affiliation: Department of Medicine, Northwestern University Feinberg School of Medicine , Chicago, IL, USA.
authors.forename: Andrew A
authors.initials: AA
authors.lastname: Davis
authors.affiliation: Department of Neurological Surgery, Northwestern University Feinberg School of Medicine , Chicago, IL, USA.
authors.forename: Derek A
authors.initials: DA
authors.lastname: Wainwright
keywords: Brain metastases; IDO; T cell therapy; glioblastoma; glioma; vaccination